Back to search
Unresectable Adenocarcinoma of the Esophagus
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Unresectable Adenocarcinoma of the Esophagus trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Unresectable Adenocarcinoma of the Esophagus trials you may qualify forThis phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leuco…
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating…
This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab…
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change…
This phase II trial tests what effects the addition of propranolol to pembrolizumab and standard chemotherapy (mFOLFOX) may have on response to treatment in pat…
Participants will receive study treatment with agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel. When participants start each agent will depend…
This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain…
This phase I trial investigates the side effects and best dose of adavosertib and how well it works when given in combination with radiation therapy in treating…